Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10283041" target="_blank" >RIV/00216208:11110/14:10283041 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/14:00075704 RIV/61989592:15110/14:33149140 RIV/00064190:_____/14:#0000807 RIV/00064165:_____/14:10283041
Result on the web
<a href="http://dx.doi.org/10.1186/1471-2407-14-323" target="_blank" >http://dx.doi.org/10.1186/1471-2407-14-323</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/1471-2407-14-323" target="_blank" >10.1186/1471-2407-14-323</a>
Alternative languages
Result language
angličtina
Original language name
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
Original language description
Background: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). Methods: A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the present analysis. Results: No statistically significant difference in survival was observed between thetwo groups, with median overall survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281). Median progress
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BMC Cancer
ISSN
1471-2407
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
May
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
—
UT code for WoS article
000336688900002
EID of the result in the Scopus database
—